Drug intelligence / Profile preview

OB-X

Development stage: Preclinical
Lead developer: Tradichem
Modality: Peptides, Small Molecules
Administration: Oral

Overview

OB-X is a proprietary blend of botanical extracts from *Melissa officinalis* (lemon balm), *Morus alba* (white mulberry), and *Artemisia vulgaris* (mugwort) formulated as a dietary supplement for obesity and weight management. It is designed to reduce adipose tissue, particularly visceral fat, by inhibiting angiogenesis in fat tissue. The active components include rosmarinic acid, 1-deoxynojirimycin, and 6,7-deoxynojirimycin. Clinical studies have shown that OB-X can significantly reduce visceral fat and waist circumference in overweight individuals when combined with caloric restriction and exercise. The mechanism of action is primarily anti-angiogenic activity within adipose tissue[2][3][4].

Brand names: OB-X TabletsOB-X®
Other names: ob-xOb-X herbal composition

Beyond the preview

Go deeper on OB-X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OB-X.

Explore the full profile